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Objective. In many rheumatoid arthritis (RA)
patients, disease is controlled with anti–tumor necrosis fac-
tor (anti-TNF) biologic therapies. However, in a significant
number of patients, the disease fails to respond to anti-TNF
therapy. We undertook the present study to examine the
hypothesis that rare and low-frequency genetic variants
might influence response to anti-TNF treatment.
Methods. We sequenced the coding region of 750
genes in 1,094 RA patients of European ancestry who were
treated with anti-TNF. After quality control, 690 genes were
included in the analysis. We applied single-variant associa-
tion and gene-based association tests to identify variants
associated with anti-TNF treatment response. In addition,
given the key mechanistic role of TNF, we performed gene
set analyses of 27 TNF pathway genes.
Results. We identified 14,420 functional variants, of
which 6,934 were predicted as nonsynonymous 2,136 of
which were further predicted to be “damaging.” Despite the
fact that the study was well powered, no single variant or
gene showed study-wide significant association with change
in the outcome measures disease activity or European
League Against Rheumatism response. Intriguingly, we
observed 3 genes, of 27 with nominal signals of association
(P < 0.05), that were involved in the TNF signaling pathway.
However, when we performed a rigorous gene set enrich-
ment analysis based on association P value ranking, we
observed no evidence of enrichment of association at genes
involved in the TNF pathway (Penrichment 5 0.15, based on
phenotype permutations).
Conclusion. Our findings suggest that rare and
low-frequency protein-coding variants in TNF signaling
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pathway genes or other genes do not contribute substan-
tially to anti-TNF treatment response in patients with RA.
Rheumatoid arthritis (RA) is effectively managed
in many cases with therapies that block the inflammatory
cytokine tumor necrosis factor (TNF) (1). However, in
approximately one-third of patients, the disease fails to
respond to anti-TNF therapy (1). The biologic mechanisms
underlying treatment failure are unknown, which limits the
development of biomarkers to guide anti-TNF use in the
clinical setting. To define genetic predictors of anti-TNF
response, investigators have conducted several genome-
wide association studies (GWAS) (2–5). To date, few stud-
ies have demonstrated significant associations between
common genetic variants and anti-TNF response, and no
loci have consistently been replicated across studies.
Importantly, genetic studies for anti-TNF response
have not investigated rare or low-frequency variants
because these were not included on previous versions of
genotyping arrays or were excluded in the analysis. These
variants are expected to be under purifying selection and
thus are potentially enriched for deleterious, protein-
coding mutations (6) that may have large effects.
We hypothesized that these rare and low-frequency
variants in relevant genes might influence response to anti-
TNF treatment. Herein we report on a rare-variant study
with anti-TNF treatment response data collected through
an international collaboration in which rare and low-
frequency variants in 750 genes from 1,094 anti-TNF–
treated RA patients were examined. Our primary outcome
measure was change in the 28-joint Disease Activity Score
(DAS28) (7) from baseline to 3–12 months after initiation
of therapy. We performed single-variant and gene-based
analysis of the association between rare/low-frequency
variants and anti-TNF treatment response.
PATIENTS AND METHODS
Samples and clinical data. All patients met the Amer-
ican College of Rheumatology 1987 criteria for RA (8) and/or
were diagnosed by a board-certified rheumatologist. Written
informed consent was provided by all patients, and institutional
review board approval was obtained at all sites. To be enrolled,
patients had to have at least moderate disease activity (DAS28
.3.2) at the initial time point. We enrolled patients from 8
cohorts in 5 countries: 1) the Autoimmune Biomarkers Collabo-
rative Network (ABCoN) (US; n 5 31), 2) the Genetics Network
Rheumatology Amsterdam (n 5 11), 3) the BeSt study (Dutch
Behandelstrategie€en voor Rheumatoide Arthritis) (n 5 46), 4)
the Biologics in Rheumatoid Arthritis Genetics and Genomics
Study Syndicate (BRAGGSS) (UK; n 5 76), 5) the Dutch Rheu-
matoid Arthritis Monitoring registry (DREAM) (n 5 189), 6)
Research in Active Rheumatoid Arthritis (ReAct) (France;
n 5 294), 7) the Consortium of Rheumatology Researchers of
North America (US; n 5 87), and 8) the Rheumatic Diseases
Portuguese Register (Reuma.pt) from the Portuguese Society of
Rheumatology (n 5 360).
The following clinical data were collected in each cohort:
1) DAS28 at baseline, 2) DAS28 from at least 1 subsequent time
point, usually 3–6 months after initiation of anti-TNF therapy, 3)
sex, 4) age, 5) concurrent methotrexate use, and 6) autoantibody
status (rheumatoid factor or anti–cyclic citrullinated peptide). We
assessed disease activity according to the DAS28; the DAS28
using the C-reactive protein level was used in the ABCoN cohort
and the DAS28 using the erythrocyte sedimentation rate (ESR) in
the others. Our primary outcome measure was change in the
DAS28 from baseline (DDAS28, i.e., baseline DAS28–ending
DAS28). Responder status according to the European League
Against Rheumatism (EULAR) criteria (9) using baseline and
ending DAS28 was a secondary outcome measure, excluding the
moderate responder category based on the hypothesis that analy-
sis of more extreme phenotypes (good responders versus non-
responders) would yield improved discrimination. We examined
clinical variables for association with the primary and secondary
outcome measures using multivariate linear and logistic regres-
sion, respectively. Age, baseline DAS28, concomitant methotrex-
ate therapy, and patient cohort were strongly associated with
DDAS28. As a result, we included these variables, together with
sex, as covariates in all subsequent genetic association tests (see
Supplementary Table 1, on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.39966/abstract).
Principal components (calculated as described below) were not
associated with DDAS28, and were not included as covariates in
the analysis.
Targeted exon sequencing. We sequenced exons tar-
geted from 828 genes, together with all reported noncoding RA
GWAS single-nucleotide polymorphisms (SNPs) and noncoding
regions overlapping histone modification marks in CD41 T cells
(which were not analyzed in the present study). In total we
sequenced ;2 Mb coding and noncoding sequences. We included
genes in known RA risk loci or associated with other autoimmune
diseases, immunodeficiency genes, genes identified from mouse
models of inflammatory arthritis, and genes in the TNF signaling
pathway.
DNA libraries from individual patients were sequenced
by pooling 96 libraries after bar-coding. Target genomic regions
were enriched using NimbleGen Sequence Capture technology.
After target capture, we loaded each pool into 2 lanes of a HiSeq
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sequencer. We aligned reads to the reference human genome
(NCBI Build37/hg19) using Burrows-Wheeler Aligner and
removed duplicate reads using Picard. In total, 95% of the
samples reached a minimum average coverage of 203 in .70%
of target regions, with 96% of the target regions in the samples
passing this initial quality control covered at $203 coverage.
Sequencing, initial quality control, and SNP calling were per-
formed at The Genome Institute. To account for population strat-
ification, we used 138 ancestry-informative markers targeted for
sequencing and passing quality control to calculate principal com-
ponents using EigenSoft version 4.2 (10), with HapMap phase 3
samples as reference populations. After applying stringent filters,
we obtained a final set of 1,094 cases of European ancestry and
restricted our analysis to 750 genes with high coverage across the
coding sequence.
SNPs were called with Samtools version 1.16 and VarScan
2.2.9, using stringent minimum coverage, mapping quality, and
strandness filters. We merged SNP calls from each sample by using
both calling algorithms and filtered variants, further removing
variants with missingness of .0.05 and a Hardy-Weinberg equilib-
rium P value of ,1027. Finally, we included only variants passing
filters in .50% of the samples in the subsequent analysis. Variants
were identified at 1 SNP/97 bp density; the transition:transversion
ratio based on the variants passing quality control was 3.17. We
used AnnoVar to annotate the variants. Variants were then
grouped as synonymous or nonsynonymous. The function of mis-
sense variants was predicted using PolyPhen-2 and Sift. Variants
were recorded as “damaging” if classified as possibly or probably
damaging with both PolyPhen-2 and Sift. We also included the
nonsense and splice variants in the “damaging” variants group.
Association analysis. We first tested the association of
each common variant (minor allele frequency [MAF] $1%) with
the primary outcome measure (DDAS28) and EULAR good
response versus no response using a linear regression model and
logistic model adjusted for covariates in Plink. We also conducted
gene-based association tests to investigate the contribution of rare
variants (defined as MAF ,1%) to anti-TNF treatment response.
This analysis was restricted to 631 genes with at least 2 different
rare variants. We used a simpler method that 1) collapses rare
variants per gene to identify carriers and noncarriers of rare
variants and 2) performs a linear regression or logistic regression
analysis to test for association between rare variant carrier status
and DDAS28 or EULAR good response versus no response. This
method entails the assumption that rare variants have a shared
direction of effect on the phenotype. We investigated the contribu-
tion of 1) all variants in the coding region including synonymous
and nonsynonymous rare variants, 2) nonsynonymous rare
variants, and 3) a subset of nonsynonymous variants that were pre-
dicted to be damaging. For each test performed, we adjusted for
covariates, and performed $1,000 permutations of the phenotype
residuals to calculate empirical P values. As a sensitivity analysis
we used the Skat-O method, which can include continuous out-
come measures as well as adjust for other covariates, and allows
for variants to have opposite effects, to assess association between
genes and DDAS28 as a sensitivity analysis. Study-wide signifi-
cance was defined using the Bonferroni method. A significance
level of P , 2.6 3 1025 was used for common variants analysis
based on 1,908 tests, and P , 7.9 3 1025 was used for gene-based
association analysis based on 631 tests. We also applied the false
discovery rate (FDR) method for multiple testing adjustments.
Data on DAS28 components in 714 patients from the
ABCoN, BRAGGSS, DREAM, ReAct, andReuma.pt cohorts
were collected. We performed a secondary gene-based associa-
tion analysis on rare coding variants with more objective
DAS28 components, i.e., ESR and swollen joint count (SJC).
We used Dlog-transformed ESR, and Dlog-transformed SJC as
outcomes, adding 1 to all SJCs to avoid values of 0.
Gene set enrichment analysis. To assess the enrich-
ment of association of rare variants in genes from the TNF signaling
pathway, we performed a gene set enrichment analysis (GSEA)
using the Kolmogorov-Smirmov test. The goal of GSEA is to deter-
mine whether P values are randomly distributed or whether the P
values of a given subgroup of sequenced genes are enriched for sig-
nificant P values compared to the other genes tested. The advan-
tage of GSEA is its relative robustness to outliers.
RESULTS
Findings of targeted exon sequencing in the RA
patients. We targeted 828 genes for exon sequencing in
1,383 RA patients of European ancestry who had received
anti-TNF treatment. After stringent quality control of the
sequencing data, 1,094 RA patients were included in sub-
sequent analyses. Details of the sample collections, as well
as clinical data, are shown in Table 1. We restricted our
analysis to 750 genes with high coverage across the coding
sequence. Among the 14,420 variants identified in these
750 genes, the largest proportion of observed variants was
intronic (49.8%), and ;15% of the variants were anno-
tated in functional domains.
Single SNP association analysis results. We first
tested 1,908 common variants (MAF $1%) individually
for association with the primary outcome measure
(DDAS28), by linear regression analysis. None of these
variants reached study-wide significance (P , 2.6 3
1025) (see Supplementary Table 2, on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39966/abstract). We also tested for asso-
ciation with the secondary outcome measure (the dichot-
omized EULAR response) using logistic regression and
found no individual variant reaching study-wide signifi-
cance. In both analyses, all variants showed FDR q val-
ues of .0.25 (Supplementary Table 2).
Gene-based association analysis results. We
then investigated the contribution of rare protein coding
variants (MAF ,1%) to treatment response. Among
14,420 variants in coding regions, there were 10,984 rare
variants. Of these rare variants, 4,050 were predicted as
synonymous and 6,934 were predicted as nonsynonymous,
2,136 of which were predicted to be damaging.
Of the 750 genes with high-quality sequencing data,
631 harbored at least 2 rare protein-coding variants. In
these genes, we tested the following for association with
DDAS28: 1) all coding rare variants, 2) all rare variants pre-
dicted to be nonsynonymous, and 3) all nonsynonymous
rare variants predicted to be damaging. However, none of
the analyses reached study-wide significance (P , 7.9 3
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1025, QQ plot for all rare variants predicted to be
nonsynonymous), and all FDR q values were .0.5 (Supple-
mentary Figure 1 and Supplementary Table 3, http://
onlinelibrary.wiley.com/doi/10.1002/art.39966/abstract).
There were 7, 3, and 7 genes with P values of ,0.01 (31, 32,
and 29 with P values of ,0.05) when the analyses were
restricted to coding variants, nonsynonymous variants, and
damaging variants, respectively. Detailed gene-based associ-
ation results for DDAS28 are presented in Supplementary
Table 3. In the analysis restricted to nonsynonymous
variants, the 3 genes with P values of ,0.01 were NFKBIA
(P 5 0.0017), AICDA (P 5 0.0043), and CDK6 (P 5
0.0058). AICDA and NFKBIA are involved in primary
immunodeficiencies, and NFKBIA is also involved in the
TNF pathway.
When we tested the association between rare
variants and TNF blockade response stratified for the 3
major anti-TNF drugs (etanercept, infliximab, and adalim-
umab), we found no significant associations (P . 0.0007)
(Supplementary Table 4, http://onlinelibrary.wiley.com/doi/
10.1002/art.39966/abstract). Similar results were observed
when we examined the secondary outcome measure,
EULAR responder versus nonresponder criteria (P .
0.004) (Supplementary Tables 3 and 4).
Table 1. Rheumatoid arthritis patient cohorts and clinical data*
Cohort
ABCoN BeSt BRAGGSS CORRONA DREAM GENRA ReAct Reuma.pt Total
Sample size
Total 31 46 76 87 189 11 294 360 1,094
EULAR response
Good responders 13 30 41 47 105 10 104 109 459
Nonresponders 7 9 28 19 83 1 50 83 280
Clinical variables
Age, years 55.4612.8 51.9614.3 52.1613.6 59.4612.8 54.3612.0 49.569.2 54.4611.2 52.5612.2 2
Female % 80.7 63 79 75.9 64.6 72.7 76.5 89.2 2
MTX treatment, % 64.5 100 89.5 66.7 76.2 90.9 47.6 82.2 2
Baseline DAS28 5.360.7 3.860.7 6.361.0 4.961.2 5.061.2 5.461.1 5.861.0 5.861.1 2
DDAS28 1.6561.34 1.6061.1 2.261.9 1.961.5 1.561.5 3.061.2 2.161.2 1.861.3 2
* Except where indicated otherwise, values are the mean 6 SD. ABCoN 5 Autoimmune Biomarkers Collaborative Network; BeSt 5
Behandelstrategie€en voor Rheumatoide Arthritis; BRAGGSS 5 Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate;
CORRONA 5 Consortium of Rheumatology Researchers of North America; DREAM 5 Dutch Rheumatoid Arthritis Monitoring registry;
GENRA 5 Genetics Network Rheumatology Amsterdam; ReAct 5 Research in Active Rheumatoid Arthritis; Reuma.pt 5 Rheumatic Diseases
Portuguese Register; EULAR 5 European League Against Rheumatism; MTX 5 methotrexate; DAS28 5 28-joint Disease Activity Score.
Figure 1. Gene set enrichment analysis for association of tumor necrosis factor signaling pathway genes (defined according to the Kyoto Ency-
clopedia of Genes and Genomes database) with the primary outcome measure, i.e., change in the 28-joint Disease Activity Score (DAS). P for
enrichment 5 0.15.
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We compared the above association results to those
obtained with Skat-O and observed a strong correlation of
the P values (R2 5 0.64) (Supplementary Figure 2, http://
onlinelibrary.wiley.com/doi/10.1002/art.39966/abstract). The
main difference was due to genes that exhibited lower P val-
ues with Skat-O, potentially due to rare variants with oppo-
site effects. Findings of a secondary gene-based analysis of
DESR and DSJC are shown in Supplementary Table 5
(http://onlinelibrary.wiley.com/doi/10.1002/art.39966/
abstract); this analysis did not reveal any study-wide signifi-
cant association.
Gene set enrichment analysis results. Of the 631
genes tested, 27 are involved in the TNF signaling pathway
(based on the Kyoto Encyclopedia of Genes and Genomes
database). Although none of the TNF pathway genes
reached study-wide significance in our gene-based tests, we
observed genes from the TNF signaling pathway with P val-
ues of ,0.05, i.e., NFKBIA (P 5 0.002, b 5 21.38), IL6
(P 5 0.02, b 5 0.42), and PTGS2 (P 5 0.04, b 5 20.85) in
the nonsynonymous variant analysis. We ranked the 631
genes by their association P values with nonsynonymous
variants, calculated the mean rank of the 27 genes from the
TNF pathway, and compared this value to the mean rank of
the remaining 604 genes. Genes in the TNF pathway were
not found to be enriched for rare variants associated with
treatment response, compared to the remaining targeted
genes (Penrichment 5 0.15) (Figure 1).
DISCUSSION
The present investigation is, to our knowledge,
the largest high-coverage exon sequencing study of anti-
TNF–treated RA patients reported to date. Overall, we
found little evidence that rare coding variants contribute
to anti-TNF response.
To investigate the contribution of rare protein-
coding variants to anti-TNF treatment response, we
selected a comprehensive list of candidate genes for exon
sequencing. Compared to exome chip array analysis, exon
sequencing ensures comprehensive capture of rare variants
Figure 2. Power to detect an association with the primary outcome measure, i.e., change in the 28-joint Disease Activity Score (DAS), at given
effect sizes and minor allele frequency (MAF) based on a sample size of 1,094 patients.
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and allows for more targeted investigation of variants in
coding regions. We sequenced up to 50 candidate genes
from the top anti-TNF GWAS hits, even though these loci
did not reach genome-wide significance, together with
genes from the TNF signaling pathway. We also sequenced
genes from RA risk loci and candidate genes related to
RA or other immune-mediated pathways, under the
hypothesis that variants in these genes could also influence
response to anti-TNF therapy. As an example illustrating a
potential connection between disease risk and treatment
response, TCF7L2 has been shown to be a risk locus for
diabetes in association studies, and clear evidence of its
association with treatment response in diabetes has been
reported (11). Using these gene selection criteria, we
tested nearly 10% of genes in the human genome. How-
ever, we recognize the limitations of candidate gene stud-
ies, many of which have tested candidates that were
subsequently shown not to be associated with the pheno-
type of interest. It remains possible that rare genetic
variants within other genes not queried in this study, or in
regulatory regions not examined in this study, might still
contribute significantly to anti-TNF response.
Expanding association studies to investigate anti-
TNF response presents several challenges. While recent
anti-TNF genetic studies (12,13), including the present
study, include .1,000 RA cases collected from interna-
tional efforts, the sample sizes remain relatively small com-
pared to other disease cohorts and limit the statistical
power to detect modest effect sizes, especially if the MAF
is low.
The power to detect an association with DDAS28
at different levels of effect size, based on our sample size
of 1,094, is plotted in Figure 2. Our study had substantial
power to detect clinically relevant single variants with large
effect. However, the power for detection of single rare
variants with more moderate effect is limited. For instance,
for a variant with an MAF of 0.1% there was only ;50%
power to detect an association with an effect size of 2
(which corresponds to DDAS28 of 3). In contrast, for
MAF 0.5% there was .80% power to detect an effect size
of 1.3 (DDAS28 ;2). We recognize that the power of the
study was limited by sample size and the low MAF. It is
therefore not surprising that no single variant we tested
achieved the study-wise significance level. Despite our
efforts to enhance power by using collapsing methods, we
did not demonstrate any study-wide significant association
in our gene-based association tests. We did observe sug-
gestive associations (P , 0.05) in the analysis restricted to
nonsynonymous variants, with the top signal mapping
NFKBIA (NF-kB inhibitor a), with a P value of 0.002
(b 5 21.38), driven by 7 rare nonsynonymous variants
(Supplementary Figure 1, on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39966/abstract). We found that NFKBIA rare variant car-
riers had smaller DDAS28 (i.e., worse response),
corresponding to an effect size of 0.9; nonetheless, given
the sample size, this association did not reach the study-
wise significance level.
In this study we used DDAS28 as an objective
marker of anti-TNF treatment response, but perhaps other
molecular correlates of treatment response might have
been more effective. It has been reported that patient
global assessment on a visual analog scale (VAS) and
tender joint count subcomponents of the DAS28 are more
correlated with psychological variables (14) and less corre-
lated with imaging scores of synovitis (15). We did test the
association with specific DAS28 components in our sec-
ondary analysis, choosing DESR and DSJC as outcome
measures because these 2 measurements are more objec-
tive than tender joint count and patient global assessment
on a VAS. We did not observe any evidence of association
of either the ESR or the SJC with any of the genes tested.
Nonetheless, DDAS28 remains the outcome that is used
clinically to make decisions regarding continuation (or dis-
continuation) of therapies, and is therefore an important
outcome measure to test for association.
In conclusion, we did not find evidence that rare
protein-coding variants in a large set of candidate genes,
including genes from the TNF signaling pathways, con-
tribute substantially to anti-TNF treatment response in
patients with RA. The identification of molecular bio-
markers for treatment response is hence an important
goal for future study.
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